Search





Search





Markets
/
Stocks
/
nasdaq-ogen
/

Oragenics Inc

OGEN

Add to Watchlist

0.588USD

+0.030+5.31%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

2.43MMarket Cap

LossP/E TTM



Oragenics Inc

0.588

+0.030+5.31%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Oragenics Inc

Currency: USD Updated: 2026-05-15

Key Insights

Oragenics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 209 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 2.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Oragenics Inc's Score

Industry at a Glance

Industry Ranking

209 / 382

Overall Ranking

427 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Oragenics Inc Highlights

StrengthsRisks

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.

Undervalued

The company’s latest PE is -0.41, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 353.35K shares, increasing 30.85% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.78.

Analyst Rating

Based on 0 analysts

Current Rating

2.000

Target Price

+250.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Oragenics Inc is 6.79, ranking 194 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.79

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Oragenics Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Oragenics Inc is 6.27, ranking 291 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.41, which is -90.61% below the recent high of -0.04 and -1092.43% above the recent low of -4.93.

Score

Industry at a Glance

Previous score

6.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 209/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

No earnings forecast score is currently available for Oragenics Inc. The Biotechnology & Medical Research industry's average is 8.13. The average price target is 2.00, with a high of 2.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Oragenics Inc is 6.07, ranking 287 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.74 and the support level at 0.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.92

Change

0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.004

Sell

RSI(14)

44.168

Neutral

STOCH(KDJ)(9,3,3)

28.009

Neutral

ATR(14)

0.042

High Vlolatility

CCI(14)

-48.405

Neutral

Williams %R

64.411

Sell

TRIX(12,20)

-0.457

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

0.575

Buy

MA10

0.596

Sell

MA20

0.617

Sell

MA50

0.668

Sell

MA100

0.738

Sell

MA200

0.943

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Oragenics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 8.15%, representing a quarter-over-quarter decrease of 38.79%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

DRW Securities, LLC

112.71K

+82.35%

Five Narrow Lane LP

82.21K

Clear Street LLC

70.62K

Geode Capital Management, L.L.C.

6.13K

Sabby Management, LLC

61.74K

+4.73%

XTX Markets LLC

33.75K

UBS Financial Services, Inc.

2.39K

+783.39%

Tower Research Capital LLC

4.55K

+2088.94%

Pope (Charles L)

849.00

Telling (Frederick W)

948.00

-18.13%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Oragenics Inc is 2.55, ranking 210 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.26. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.